stockrow
Friday 6 November 2026
Export WGS’s income statement to Excel — free account
GeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
62.46
1.90
−2.95%
Follow WGS
Alert me
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 2 | 3 | 5 | 6 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 | 0.07 | 0.01 | 0.32 | 6.77 | 8.71 |
Altman Z-Score |
— | — | (3.82) | (2.85) | (7.04) | (4.72) | 3.56 | 7.80 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 261.20 |
Altman Z″-Score (non-manufacturers) |
— | — | (8.10) | (1.82) | (14.57) | (9.83) | (7.17) | (5.22) |
P/Operating CF |
— | 0.00 | 8.21 | (0.28) | (0.04) | (2.15) | (649.34) | (1,205.56) |
Beneish M-Score |
— | — | — | — | — | (3.20) | (2.58) | (2.36) |
P/B ratio |
— | 0.00 | 1.43 | 0.04 | 0.01 | 0.28 | 8.43 | 12.09 |
Price to Tangible BV |
— | 0.00 | 1.43 | 0.04 | 0.04 | 1.16 | 23.85 | 29.52 |
EV/Sales |
— | 0.00 | 0.00 | (1.77) | (0.49) | (0.07) | 6.47 | 8.43 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.88 | 0.19 | 0.09 | 0.00 | 296.54 |
EV/Operating CF |
— | 0.00 | 0.00 | 1.97 | 0.36 | 0.07 | (69.40) | 108.24 |
EV/FCF |
— | 0.00 | 0.00 | 1.78 | 0.34 | 0.07 | (58.19) | 252.56 |
Quick Ratio |
— | — | 1.91 | 4.22 | 1.16 | 2.77 | 3.26 | 2.26 |
Current Ratio |
— | — | 2.37 | 4.77 | 1.47 | 3.10 | 3.61 | 2.46 |
Net Debt/EBITDA |
— | 0.00 | 0.30 | 0.92 | 0.19 | 0.53 | 70.85 | (10.13) |
Debt/Assets |
0.00% | 0.00% | 15.80% | 1.99% | 1.27% | 12.58% | 12.38% | 9.20% |
Debt/Equity |
— | 0.00 | 9.06 | 0.03 | 0.02 | 0.23 | 0.21 | 0.16 |
Asset Turnover |
— | 0.00 | 1.43 | 0.53 | 0.45 | 0.45 | 0.73 | 0.91 |
Operating CF/Net income |
— | 0.57 | 0.39 | 0.78 | 0.58 | 1.02 | 0.55 | (1.58) |
Capex/Depreciation |
— | (2.41) | (2.72) | (0.95) | (0.24) | (0.05) | (0.25) | (0.75) |
Interest Coverage |
— | (38.84) | (97.81) | (157.37) | (208.19) | — | — | — |
| — | 0.00% | (831.46%) | (845.41%) | (171.07%) | (72.97%) | (22.10%) | (7.60%) | |
| — | 0.00% | (191.81%) | (60.91%) | (105.06%) | (38.64%) | (12.48%) | (4.46%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (306.78%) | (74.97%) | (9.30%) | (4.42%) |
Return on Tangible Assets |
— | 0.00% | (147.36%) | (55.15%) | (458.05%) | (112.67%) | (29.70%) | (10.25%) |
Average Days of Receivables |
— | 0.00 | 65.81 | 45.69 | 67.41 | 59.13 | 44.97 | 63.49 |
Research and Development Expense of Revenue |
— | 17.80% | 40.54% | 49.56% | 36.73% | 28.76% | 14.97% | 16.85% |
Selling, General and Administrative Expense of Revenue |
— | 35.09% | 91.41% | 150.20% | 144.12% | 98.72% | 56.27% | 55.95% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.38 | 0.41 | 0.38 | 0.35 |
Share Based Compensation of Revenue |
— | 2.79% | 67.05% | 103.41% | 17.88% | (0.16%) | 2.99% | 7.52% |
Graham Net Nets |
— | 0.00 | (0.02) | 21.74 | (8.59) | (0.13) | 0.01 | 0.01 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | 0.00% | 0.00% | (289,043.97%) | (19,008.54%) | (284.55%) | (2.55%) | (0.56%) |
Free Cash Flow Yield |
— | 0.00% | 0.00% | (1,446.20%) | (11,634.16%) | (283.29%) | (1.64%) | 0.38% |
Revenue per Share |
— | 0.00 | 1,153,344.48 | 64.80 | 22.93 | 8.33 | 11.36 | 14.93 |
Operating CF per Share |
— | 0.00 | (598,970.93) | (58.15) | (31.18) | (7.41) | (1.06) | 1.16 |
Capex per Share |
— | 0.00 | (205,647.03) | (6.35) | (1.40) | (0.07) | (0.20) | (0.66) |
Free Cash Flow per Share |
— | 0.00 | (804,617.96) | (64.50) | (32.58) | (7.48) | (1.26) | 0.50 |
Cash per Share |
— | 0.00 | 695,472.09 | 122.32 | 12.11 | 5.35 | 5.25 | 5.98 |
Shareholders Equity per Share |
— | 0.00 | 28,222.28 | 118.52 | 24.78 | 9.38 | 9.12 | 10.76 |
Interest Debt per Share |
— | 0.00 | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 28,222.28 | 118.52 | 24.78 | 9.38 | 9.12 | 10.76 |
Free Cash Flow |
— | (34.18) | (125.10) | (211.22) | (333.48) | (181.82) | (33.99) | 14.26 |
Working Capital |
— | — | 100.67 | 382.26 | 68.33 | 123.52 | 143.15 | 159.38 |
Capital Expenditures |
— | (15.46) | (31.97) | (20.79) | (14.32) | (1.68) | (5.49) | (19.02) |
Net Current Asset Value |
— | 0.00 | (73.15) | 317.55 | (24.61) | (8.40) | 23.84 | 52.76 |
EV/EBIT |
— | 0.00 | 0.00 | 0.84 | 0.17 | 0.07 | 0.00 | 0.00 |
Capex to Sales |
— | 0.08 | 0.18 | 0.10 | 0.06 | 0.01 | 0.02 | 0.04 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.19 | 0.35 | 1.15 | 1.04 | 0.67 | 0.55 |
Cash ROIC |
— | 0.00% | (82.16%) | (26.41%) | (86.87%) | (44.26%) | (7.75%) | 2.70% |
Accounts Receivable Turnover |
— | 0.00 | 6.09 | 7.21 | 6.71 | 5.32 | 8.67 | 7.63 |
Accounts Payable Turnover |
— | 0.00 | 4.91 | 6.41 | 4.04 | 1.84 | 3.25 | 2.92 |
Inventory Turnover |
— | 0.00 | 6.00 | 7.83 | 11.10 | 10.03 | 11.43 | 10.52 |
Average Days of Payables |
— | 0.00 | 55.67 | 71.30 | 118.50 | 121.46 | 101.83 | 162.64 |
Days of Inventory on Hand |
— | 0.00 | 51.98 | 53.37 | 19.08 | 28.46 | 35.00 | 39.36 |
Average Receivables |
— | — | 29.45 | 29.45 | 34.95 | 38.08 | 35.22 | 56.00 |
Average Payables |
— | — | 35.72 | 35.72 | 64.79 | 61.17 | 34.22 | 44.31 |
Average Inventory |
— | — | 29.21 | 29.21 | 23.56 | 11.22 | 9.71 | 12.30 |
Average Assets |
— | 0.00 | 125.82 | 402.87 | 522.52 | 454.85 | 419.07 | 471.55 |
Average Common Equity |
— | — | 29.03 | 29.03 | 320.90 | 240.86 | 236.63 | 276.71 |
Columns are period end dates · fundamentals updated 26 Oct 2026